Medical devices firm Deltex Medical Group (LON:DEMG) has received approval to launch its CardioQ-EDM monitor in the US by the country’s Food and Drug Administration. Deltex is now able to market and sell the device in the US with immediate effect, it announced today. Cardio-EDM is similar to CardioQ-ODM (oesophageal Doppler monitor) – Deltex’s blood monitoring system that requires a new disposable probe every time the system is used on a new patient, meaning that Deltex gets a consumables-driven revenue stream as well as income from sales of the device itself.
